==================================CMR09==================================
9.   Case reports or described mechanisms of vestibular toxicity
     from high dose cisplatin  (nausea, vomiting, ototoxicity).
     CarboPlatin potentiation of cisplatin induced neurotoxicity.
     Incidence of neurotoxicity from CarboPlatin.
1
UI  - 86309943
AU  - Schweitzer VG ; Rarey KE ; Dolan DF ; Abrams GE ; Sheridan C
TI  - Vestibular morphological analysis of the effects of cisplatin vs.
      platinum analogs, CBDCA (JM-8) and CHIP (JM-9).
AB  - Synthetic second generation chemotherapeutic platinum analogs are
      presently being tested to identify an analog with greater
      antitumor activity, but less ototoxicity and nephrotoxicity than
      cisplatin. The objective of this study was to analyze potential
      vestibular effects of cisplatin and of the two platinum analogs,
      CBDCA (cis-diammine 1,1-cyclobutane dicarboxylato [2]-0,0(1)
      platinum or JM-8) and CHIP
      (cis-dichlorotrans-dihydroxy-bis(isopropylamine) platinum [IV] or
      JM-9) using scanning and transmission electron microscopy of
      vestibular neuroepithelium from the albino guinea pig. Vestibular
      neuroepithelial damage was not demonstrated in either cisplatin-
      or the analog-treated animals when administered at equitoxic
      doses.
MH  - Animal ; Cisplatin/*TOXICITY ; Comparative Study ; Guinea Pigs ;
      Microscopy, Electron, Scanning ; Organoplatinum Compounds/
      *TOXICITY ; Saccule and Utricle/DRUG EFFECTS/ULTRASTRUCTURE ;
      Support, Non-U.S. Gov't ; Support, U.S. Gov't, P.H.S. ;
      Vestibular Apparatus/*DRUG EFFECTS/ULTRASTRUCTURE
SO  - Laryngoscope 1986 Sep;96(9 Pt 1):959-74
2
UI  - 86244777
AU  - Bacha DM ; Caparros-Sison B ; Allen JA ; Walker R ; Tan CT
TI  - Phase I study of carboplatin (CBDCA) in children with cancer.
AB  - A phase I study of carboplatin (CBDCA) was performed in 40
      children with advanced cancer. A single course of CBDCA consisted
      of 4 weekly 1-hour infusions followed by a 2-week rest. The
      starting dose of 100 mg/m2/week was 66% of the maximum tolerated
      dose in adults. Escalated dose levels given were: 125, 150, 175,
      and 210 mg/m2. Myelosuppression was dose limiting, with
      thrombocytopenia more pronounced than leukopenia. There was no
      evidence of cumulative toxicity. The maximum tolerated dose for
      children with solid tumors was 210 mg/m2/week X 4. Other side
      effects included transient nausea and vomiting at the higher dose
      levels and non-dose-related, reversible changes in creatinine
      clearance. One patient developed hives. No hepatic toxicity was
      seen. Among the 28 evaluable patients with solid tumors, one of
      ten with osteogenic sarcoma had complete disappearance of a lung
      nodule for 15+ months. Two of four patients with medulloblastoma
      had partial responses by clinical and computerized tomographic
      scan for 4 and 10 months. All three responders had received prior
      cisplatin therapy. CBDCA has major advantages over cisplatin in
      terms of reduced toxicity. Responses observed in patients
      previously treated with cisplatin are encouraging. The
      recommended phase II dose for children with solid tumors is 175
      mg/m2/week X 4 with a 2-week rest.
MH  - Adolescence ; Antineoplastic Agents/ADVERSE EFFECTS/*THERAPEUTIC
      USE ; Case Report ; Cerebellar Neoplasms/DRUG THERAPY ; Child ;
      Child, Preschool ; Creatinine/BLOOD ; Drug Administration
      Schedule ; Drug Evaluation ; Female ; Femoral Neoplasms/DRUG
      THERAPY ; Gastrointestinal Diseases/CHEMICALLY INDUCED ;
      Hematologic Diseases/CHEMICALLY INDUCED ; Human ; Kidney Diseases/
      CHEMICALLY INDUCED ; Male ; Medulloblastoma/DRUG THERAPY ;
      Neoplasms/BLOOD/*DRUG THERAPY ; Organoplatinum Compounds/ADVERSE
      EFFECTS/*THERAPEUTIC USE ; Sarcoma, Osteogenic/DRUG THERAPY
SO  - Cancer Treat Rep 1986 Jul;70(7):865-9